2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1285600973 MD
Verify on CMS →

RORY BREIDBART, MD

Endocrinology, Diabetes & Metabolism Physician in NEW HYDE PARK, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
8K
Medicare Part D claims · 961 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
46%
generic claims · 54% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
88.8314/100
▲ 6 pts above national avg 83.1 · [object Object]
Industry payments
$1.8K
87 payments · CMS Open Payments (Sunshine Act)
What the federal data reveals: RORY BREIDBART, MD is a Endocrinology, Diabetes & Metabolism Physician ([object Object]) practicing in NEW HYDE PARK, New York with a Medicare Part D prescribing footprint of 8K claims across 961 beneficiaries — 54% brand-name prescribing . Their CMS MIPS Final Score of 88.8314/100 (national average: 83.1) reflects performance across Quality, Cost, Interoperability, and Improvement Activities . Industry payments of $1.8K across 87 transactions are disclosed under CMS Open Payments (Sunshine Act).

What stands out: RORY BREIDBART, MD reported a CMS MIPS final score of 88.8314 out of 100, above the 83.1 national average, and filed 8,089 Medicare Part D claims in 2023. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.

Board certification likely (heuristic — not verified)

RORY BREIDBART, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

RORY BREIDBART, MD at a glance

High performer (top quartile)

NPI registry status

Active

Issued 02/23/2006

NPI 1285600973

Primary specialty

Endocrinology, Diabetes & Metabolism Physician

Mid-sized

7,852 US NPIs in this specialty

Medicare Part D claims

8,089 207% vs specialty avg

2023 prescription claims

Specialty avg: 2,639

MIPS final score

88.8314/100 5.731400000000008% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in New York

How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among New York providers

New York providers

Endocrinology, Diabetes & Metabolism Physician share within New York

1. Endocrinology, Diabetes & Metabolism Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Endocrinology, Diabetes & Metabolism Physician share within New York

Medicare quality performance — MIPS

RORY BREIDBART, MD's 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average

High performer (top quartile)
MIPS Final Score
88.8314/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 88.8314/100 vs national avg 83.1

0%100%National avg83%88.8%
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 88.8314/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

RORY BREIDBART, MD is a Endocrinology, Diabetes & Metabolism Physician provider practicing in NEW HYDE PARK, New York, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: MD. NPI: 1285600973. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

RORY BREIDBART, MD appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding MD credentials at 1999 MARCUS AVE STE 212, NEW HYDE PARK, NY, 11042, with a listed phone of (516) 467-8600. NPI 1285600973 was issued on 02/23/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what BREIDBART most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 8,089 prescription claims written by this provider, covering 961 Medicare beneficiaries and totaling roughly $4.1 million in drug spend, split 54% brand-name and 46% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 88.8314/100 for the 2023 performance year (Quality 100, Cost 50.5567), compared with the national average of 83.1.

Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

1999 MARCUS AVE STE 212
NEW HYDE PARK, NY 11042

Provider Details

NPI 1285600973
Specialty Endocrinology, Diabetes & Metabolism Physician
Credentials MD
Gender Male
NPI Issued 02/23/2006

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

88.8314
Final Score
Avg: 83.1
100
Quality
50.5567
Cost

Reporting: Group practice

Hospital and facility affiliations

Facilities where RORY BREIDBART, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

NEW YORK UNIVERSITY
NEW YORK, NY

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for RORY BREIDBART, MD. Source: openpaymentsdata.cms.gov.

Total received

$1.8K

Largest payer

Xeris Pharmaceuticals, Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — New York NYSBPMC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to RORY BREIDBART, MD. To verify RORY BREIDBART, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases

NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Brand-heavy

RORY BREIDBART, MD — brand share 54.0%
Specialty average (est.)

54% brand-name claims vs 46% generic, on 8,089 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

8,089
Total Claims
$4.1M
Total Drug Cost
961
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
18,911
Total Day Supply
563,568
Brand vs Generic
54% brand / 46% generic
Brand Drug Cost
$3.9M
Generic Drug Cost
$145K
Antibiotic Claims
13

Patient Demographics

Average Patient Age
75.4 years
Avg HCC Risk Score
1.34
Gender Split
52% female / 48% male
Age Distribution
<65: 35, 65-74: 423, 75-84: 392, 85+: 111

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Levothyroxine Sodium
818
Synthroid
Levothyroxine Sodium
702
Mounjaro
Tirzepatide
633
Metformin Hcl
569
Trulicity
Dulaglutide
442
Jardiance
Empagliflozin
305
Glimepiride
270
Januvia
Sitagliptin Phosphate
264
Atorvastatin Calcium
256
Farxiga
Dapagliflozin Propanediol
187

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Endocrinology, Diabetes & Metabolism Physician Overview

How RORY BREIDBART, MD fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.

7,852
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider

RORY BREIDBART, MD's 8,089 claims are above the specialty average of 2,639.

Nearby Endocrinology, Diabetes & Metabolism Physician Providers in New York

Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as BREIDBART.

Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is RORY BREIDBART, MD's specialty?
RORY BREIDBART, MD specializes in Endocrinology, Diabetes & Metabolism Physician and practices in NEW HYDE PARK, New York. Credentials: MD.
How much does RORY BREIDBART, MD prescribe under Medicare Part D?
In 2023, RORY BREIDBART, MD wrote 8,089 Medicare Part D claims totaling $4.1M in drug costs for 961 beneficiaries.
What is RORY BREIDBART, MD's Medicare quality score?
RORY BREIDBART, MD has a CMS MIPS Final Score of 88.8314/100 (Quality: 100, Cost: 50.5567). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is RORY BREIDBART, MD located?
RORY BREIDBART, MD is located at 1999 MARCUS AVE STE 212, NEW HYDE PARK, NY, 11042. Phone: (516) 467-8600.
What is RORY BREIDBART, MD's NPI number?
RORY BREIDBART, MD's National Provider Identifier (NPI) is 1285600973, issued on 02/23/2006.
Does RORY BREIDBART, MD prescribe more brand-name or generic drugs?
RORY BREIDBART, MD's prescribing is 54% brand-name and 46% generic drugs by claim count, with $3.9M in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US?
There are 7,852 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does RORY BREIDBART, MD prescribe most often?
Based on 2023 Medicare Part D data, RORY BREIDBART, MD's most frequently prescribed drugs include Levothyroxine Sodium, Synthroid, Mounjaro. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does RORY BREIDBART, MD accept Medicare?
RORY BREIDBART, MD appears in CMS Medicare data with 8,089 Part D claims and 961 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify RORY BREIDBART, MD's credentials?
RORY BREIDBART, MD's NPI is 1285600973 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology